middle.news
Chimeric pivots to in vivo CAR-T after halting unsafe CHM-2101 dose
5:13pm on Thursday 29th of October, 2026 AEDT
•
Biotechnology
Read Story
Chimeric pivots to in vivo CAR-T after halting unsafe CHM-2101 dose
5:13pm on Thursday 29th of October, 2026 AEDT
Key Points
CHM-2101 enrolment and dosing halted after dose-limiting toxicities
Board will not progress the autologous CAR-T product in its current form
$1.35 million cash balance equates to 0.80 quarters of reported funding
Trading suspension remains in place pending audited FY2026 accounts
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE